Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives

New device, new trial, same flop. That is the story at Satsuma Pharmaceuticals, which suffered a second stock-crushing phase 3 belly-flop after tweaks to its migraine nasal drug delivery device failed to yield an asset capable of beating placebo.